These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1086 related articles for article (PubMed ID: 25453876)

  • 1. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial.
    Zeller T; Peeters P; Bosiers M; Lammer J; Brechtel K; Scheinert D; Rastan A; Noory E; Beschorner U
    J Endovasc Ther; 2014 Dec; 21(6):765-74. PubMed ID: 25453876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
    J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease.
    Ullery BW; Tran K; Itoga N; Casey K; Dalman RL; Lee JT
    J Vasc Surg; 2015 Jun; 61(6):1479-88. PubMed ID: 25704407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-Year Results of a Multicenter Randomized Controlled Trial Comparing Heparin-Bonded Endoluminal to Femoropopliteal Bypass.
    Reijnen MMPJ; van Walraven LA; Fritschy WM; Lensvelt MMA; Zeebregts CJ; Lemson MS; Wikkeling ORM; Smeets L; Holewijn S
    JACC Cardiovasc Interv; 2017 Nov; 10(22):2320-2331. PubMed ID: 29169500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery.
    Ohki T; Kichikawa K; Yokoi H; Iida O; Yamaoka T; Maeda K; Kanaoka Y
    J Vasc Surg; 2021 Dec; 74(6):1958-1967.e2. PubMed ID: 34182032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial.
    Saxon RR; Chervu A; Jones PA; Bajwa TK; Gable DR; Soukas PA; Begg RJ; Adams JG; Ansel GM; Schneider DB; Eichler CM; Rush MJ
    J Vasc Interv Radiol; 2013 Feb; 24(2):165-73; quiz 174. PubMed ID: 23369553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial comparing the safety and efficacy between the FUSION BIOLINE heparin-coated vascular graft and the standard expanded polytetrafluoroethylene graft for femoropopliteal bypass.
    Lumsden AB; Morrissey NJ;
    J Vasc Surg; 2015 Mar; 61(3):703-12.e1. PubMed ID: 25720929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions.
    Ohki T; Kichikawa K; Yokoi H; Uematsu M; Yamaoka T; Maeda K; Kanaoka Y
    J Vasc Surg; 2017 Jul; 66(1):130-142.e1. PubMed ID: 28400218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease.
    Geraghty PJ; Mewissen MW; Jaff MR; Ansel GM;
    J Vasc Surg; 2013 Aug; 58(2):386-95.e4. PubMed ID: 23676191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-bonded expanded polytetrafluoroethylene femoropopliteal bypass grafts outperform expanded polytetrafluoroethylene grafts without heparin in a long-term comparison.
    Samson RH; Morales R; Showalter DP; Lepore MR; Nair DG
    J Vasc Surg; 2016 Sep; 64(3):638-47. PubMed ID: 27139782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of the heparin-bonded Viabahn stent graft in femoropopliteal TASC C and D lesions with a covered stent length of minimum 25 cm.
    Uhl C; Dadras A; Reichmann F; Betz T; Zorger N; Toepel I; Steinbauer M
    Vascular; 2019 Oct; 27(5):553-559. PubMed ID: 30917750
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
    McQuade K; Gable D; Hohman S; Pearl G; Theune B
    J Vasc Surg; 2009 Jan; 49(1):109-15, 116.e1-9; discussion 116. PubMed ID: 19028055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
    McQuade K; Gable D; Pearl G; Theune B; Black S
    J Vasc Surg; 2010 Sep; 52(3):584-90; discussion 590-1, 591.e1-591.e7. PubMed ID: 20598480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of the FUSION vascular graft for above-knee femoropopliteal bypass.
    Assadian A; Eckstein HH;
    J Vasc Surg; 2015 Mar; 61(3):713-9.e1. PubMed ID: 25498193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
    Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ
    J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the standard bolia technique versus subintimal recanalization plus Viabahn stent graft in the management of femoro-popliteal occlusions.
    Boufi M; Dona B; Orsini B; Auquier P; Hartung O; Alimi YS
    J Vasc Surg; 2010 Nov; 52(5):1211-7. PubMed ID: 20692789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year outcomes of the GORE VIABAHN Endoprosthesis for the treatment of complex femoropopliteal lesions from a Japanese postmarket surveillance study.
    Iida O; Ohki T; Soga Y; Suematsu N; Nakama T; Yamaoka T; Tobita K; Ichihashi S
    Vasc Med; 2024 Aug; 29(4):416-423. PubMed ID: 38544413
    [No Abstract]   [Full Text] [Related]  

  • 18. Heparin-Bonded Stent-Graft for the Treatment of TASC II C and D Femoropopliteal Lesions: 36-Month Results of the Viabahn 25 cm Trial.
    Böhme T; Noory E; Brechtel K; Scheinert D; Bosiers M; Beschorner U; Zeller T
    J Endovasc Ther; 2021 Apr; 28(2):222-228. PubMed ID: 33044119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study.
    Veraldi GF; Mezzetto L; Macrì M; Criscenti P; Corvasce A; Poli R
    Ann Vasc Surg; 2018 Feb; 47():179-187. PubMed ID: 28943491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis.
    Mohr PJ; Oyama JK; Luu JT; Stinis CT
    Cardiovasc Revasc Med; 2015 Dec; 16(8):465-8. PubMed ID: 26483319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.